Cell Therapy Development for Leukemia
Cell therapy is quite a promising breakthrough into leukemia therapy. By modifying either immune cells or stem cells, it precisely identifies and works to eliminate leukemia cells. Alfa Cytology is working on the development of leukemia cell therapies, a single-source service from project planning through total solution design.
Introduction to Cell Therapy for Leukemia
Leukemia is a cancer of the blood. The disease exhibits some features of abnormal proliferation of white blood cells, which can slowly kill or invade healthy cells. Traditional therapy, including chemotherapy and radiotherapy, had been in use for many years and brought unfairly many side effects and failed to provide a complete and indefinite cure. Cell therapy technology, most notably chimeric antigen receptor T cell (CAR-T) therapy, has recently created new hopes for leukemia treatment. Other new cell therapies for leukemia are also prospected to arise, which instead can have further precision in targeting leukemia cells and in activating and augmenting the action of the immune system in the battle against cancer.
Fig. 1. Diagram of CAR T cell therapy process. (Hucks, G., & Rheingold, S.R., 2019)
Advantages of Cell Therapy
Cellular therapy boasts some key advantages over these classic treatments:
| Advantages | Description |
|---|---|
| Precision Strike | Genetically modified immune cells can specifically identify specific markers on the surface of the cancer cells and selectively kill the cancer cells whilst sparing most of the healthy cells, and therefore mitigating side effects. |
| Personalized Therapy | Different patients respond to therapy differently, so treatment must be personalized. By extracting immune cells from the patient's own body, modifying and expanding them outside the body, then reinfusing them into the patient, the cellular therapy becomes individualized. |
| Long-lasting effect | Unlike traditional treatments that require multiple treatments, the modified cells can survive in the body for a long period of time and continue to remove cancer cells, which helps control the disease for a long period of time and prolongs the patient's survival. |
The development of leukemia cell therapy is expected to improve leukemia outcomes and change the landscape of cancer therapy. As scientific knowledge and technology advance, Alfa Cytology is committed to developing more advanced and targeted cell therapy for various leukemia subtypes, including exploring different antigen targets, optimizing cell design, investigating combination therapies, and studying how to minimize side effects. According to cell types, it can be divided into the following categories.
T Cell Immunotherapy
T-cell immunotherapy is a revolutionary approach to cancer therapy. It harnesses the power of its immune system to fight cancer. In particular, it has shown remarkable results in blood cancers, such as leukemia and lymphoma. Alfa Cytology provides comprehensive T-cell immunotherapy development services.
Natural Killer Cell Therapy
Natural killer (NK) cell therapy is an emerging field of cancer therapy. NK cells recognize and destroy cancer cells without prior sensitization or genetic modification. The therapy has shown good results in hematological malignancies and solid tumors. Alfa Cytology provides comprehensive NK cell therapy development services.
Cytokine-Induced Killer Cell Therapy
Cytokine-induced killing (CIK) cell therapy is a promising immunotherapy approach with strong specificity, weak side effects, and the potential to target multiple leukemia subtypes. Alfa Cytology provides comprehensive cytokine-induced killer cell therapy development services.
Stem Cell Therapy
Stem cell therapy uses the regenerative potential of stem cells to treat leukemia. Stem cells have a unique ability to differentiate into specific cell types that can repair damaged tissues and organs. Alfa Cytology provides comprehensive stem cell therapy development services.
The Workflow of the Cell Therapy Development
and Activation
Contact us
Cell therapy is still a developing field with many challenges, including potential side effects, widespread accessibility and affordability, and process optimization. Therefore, Alfa Cytology is committed to continuing to address these issues to make cell therapy an exciting area of medical advancement, improving therapy outcomes. Please contact us immediately to discuss how our cell therapy development service can contribute to the success of your research.
Reference
- Hucks, G., Rheingold, S.R. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. Blood Cancer Journal 9, 10 (2019). https://doi.org/10.1038/s41408-018-0164-6.